John V. Oyler, Founder, Chairman & CEO at BeOne Medicines, shared a post on LinkedIn:
“Fifteen years ago, my co-founder Xiaodong Wang and I embarked on a journey fueled by a bold conviction: that cancer care could be fundamentally transformed through innovation.
believe that breakthrough medicines should not only be effective but also accessible, ensuring that every patient, no matter where they live, can benefit from the best that science has to offer.
The Beginning of a Mission
When we launched the company in 2010, our mission was clear: to harness cutting-edge science to revolutionize cancer treatment in ways that had never been done before. We forged a path that diverged from traditional models, driven by the idea that true innovation comes from challenging the status quo. With no guarantees in sight, we relied on the enduring power of collaboration, scientific inquiry, and a shared purpose. This transformative approach established us as a research-driven organization with a global mindset from day one. Our initial discoveries shaped our identity, guiding us forward with curiosity, rigor, and an unwavering determination to convert potential into tangible progress — bringing the future of cancer care closer.
Growing Through Collaboration
Our remarkable growth over the years is a testament not only to our commitment to innovation, but also to the power of collaboration. By partnering with world-class research institutions, biotech and global biopharma companies who saw our potential right away, we accelerated discovery and expanded our capabilities.
By 2016, we had become a publicly listed company – a pivotal moment in our journey. This unlocked new avenues for growth and facilitated our expansion into Europe, placing us within a key epicenter of the world’s biotech ecosystem.
Reaching Patients Around the World
As we evolved, over the next several years, our focus turned toward ensuring that scientific breakthroughs we achieved would reach those in need. We strengthened our clinical and manufacturing capabilities, expanded our global teams, and built the infrastructure necessary to deliver innovation faster and more efficiently.
In just over a decade, we expanded from a small R&D company into a fully integrated global organization boasting thousands of dedicated employees and operations spanning six continents.
In 2019, the U.S. FDA granted accelerated approval to treat patients with Mantle Cell Lymphoma using our BTK inhibitor – a defining milestone. Since then, our therapies have received approvals across Asia, Europe, and Latin America, expanding access to people living with cancer in more than 75 countries. Every milestone marks more than regulatory progress – it’s a step toward realizing our vision of reaching patients around the world.
Innovation Without Borders
In 2021, we celebrated a monumental achievement by becoming the first biotech in history to be listed simultaneously on major exchanges in the United States, Hong Kong, and Shanghai. A development that underscored our belief that innovation knows no borders.
That same year, we broke ground on our U.S. biologics and R&D campus in Hopewell, New Jersey, laying the foundation for scientific excellence and manufacturing capabilities in the United States. Our enhanced research and development capabilities in Asia and Europe ensure that discovery and development happen around the clock, transcending geographical constraints.
Expanding Our Impact
Our journey has always been about more than science – it’s about impact. We’ve launched programs to expand access to life-changing cancer treatments in low- and middle-income countries. Additionally, our volunteer and sustainability initiatives reflect our commitment to our broad responsibility to both people and the planet.
In recent years, we surpassed a significant milestone: more than one million patients have been treated with our medicines, a testament to the relentless dedication of our global teams and partners.
Becoming BeOne
Now, as we celebrate our 15th anniversary, we are embracing a new chapter in our evolution. Our rebranding to BeOne Medicines, alongside our new stock ticker ONC, reflects our unified purpose: to stop cancer and to foster collaboration and scientific excellence.
Our strategic redomiciliation to Basel, Switzerland – a global hub for life sciences – represents both our growth trajectory and our long-term commitment to operating as a truly international company.
Cancer has no borders. Neither do we. Today, BeOne has a presence in more than 75 countries and a team of nearly 12,000 people united in pursuit of a singular mission: to build the world’s leading oncology company – powered by a prolific pipeline, scientific excellence and exceptional speed in bringing the future of cancer care closer to patients everywhere. Together, we are how the world stops cancer.
Looking Ahead
The story of BeOne is a testament to the transformative power of science united with purpose. We began with a vision to make innovation more human – and today, that vision continues to guide everything we do.
As we look to the future, we remain focused on pushing the boundaries of what’s possible in oncology. Our mission is clear: to deepen access to innovative treatments where they are needed most and ensure that no patient is left behind. Together – as one unified team – we stand poised to change the world of cancer care for the better.
For a detailed overview of our journey and achievements over the past 15 years, I invite you to explore our full timeline on our global corporate website:https://beonemedicines.com/about/history/ Thank you for being part of our journey!”